Vertriebsvereinbarung für Zemcelpro® in Argentinien, Hongkong und Singapur bekannt gegeben

PartnershipZemcelproPositive

AI Analysis

Summary

FarmaMondo announced distribution rights for Zemcelpro (Dorocubicel), an UM171 cell therapy approved by the European Commission for treating certain hematological malignancies, in Argentina, Hong Kong, and Singapore.

Outcome Details

Distribution rights agreement announced for Zemcelpro in Argentina, Hong Kong, and Singapore

Importance:5/10

Sentiment:

0.40

distribution agreementcell therapyinternational expansionhematological malignancies

Read the original article

Published by PR Newswire Biotech on July 16, 2026 5:04 PM

Read Original